In silico molecular docking and in vitro analysis of ethanolic extract Ocimum sanctum Linn.: Inhibitory and apoptotic effects against non-small cell lung cancer
-
Published:2021-12-28
Issue:
Volume:
Page:3175-3187
-
ISSN:2231-0916
-
Container-title:Veterinary World
-
language:en
-
Short-container-title:Vet World
Author:
Kustiati Ulayatul1ORCID, Dewi Ratih T. S.2ORCID, Dwi Aris Agung N.3ORCID, Kusindarta Dwi Liliek4ORCID, Wihadmadyatami Hevi4ORCID
Affiliation:
1. Post Graduate Student of Sain Veteriner, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia. 2. Department of Biology, Faculty of Mathematics and Natural Sciences, and Research center of Smart Molecule of Natural Genetics Resources, Brawijaya University, Indonesia. 3. Department of Pharmacology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia. 4. Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia.
Abstract
Background and Aim: Lung cancer, especially non-small cell lung cancer (NSCLC), has been identified as the leading cause of cancer deaths worldwide. The mortality rate from lung cancer has been estimated to be 18.4%. Until now, conventional treatments have not yielded optimal results, thus necessitating an investigation into the use of traditional herbal plants as potential candidates for its treatment. This study aimed to determine the inhibitory and apoptotic activity of the ethanolic extract from Ocimum sanctum Linn. (EEOS) by in silico molecular docking and through in vitro studies using NSCLC cells (A549 cell line).
Materials and Methods: Dried simplicia of Ocimum sanctum was converted into EEOS using the maceration method. Spectrophotometry was then employed to analyze the EEOS compound. The known main active compounds were further analyzed for inhibitory and apoptotic effects on gene signaling using in silico molecular docking involving the downloading of active compounds from PubChem and target proteins from the Protein Data Bank; the active compounds and proteins were then prepared using the Discovery Studio software v. 19.0.0 and the PyRX 0.8 program, interacted with the HEX 8.0.0 program, and visualized with the Discovery Studio Visualizer v. 19.0. Finally, an in vitro analysis was performed using an antiproliferative-cytotoxic test (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay in the NSCLC A549 cell line).
Results: The analysis revealed that the active compounds in the ethanolic extract were dominated by quercetin (flavonoids) (47.23% b/b) and eugenol (phenolic) (12.14% b/b). These active compounds interacted with the active sites (residual amino acids) of the αvβ3 integrin, α5β1 integrin, caspase-3, caspase-9, and vascular endothelial growth factor. Hydrogen bonds and Pi-cation and Pi-alkyl interactions were involved in the relationships between the active compounds and the active sites and thus may reveal an antioxidant property of the extract. Furthermore, in vitro analysis showed the inhibitory and antiproliferative effects of the EEOS against non-small cell cancer (A549).
Conclusion: Taken together, our data showed the ability of EEOS as an inhibitor and apoptotic agent for lung cancer; however, further research is needed to determine the exact mechanism of EEOS as an herbal medication.
Funder
Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia
Publisher
Veterinary World
Subject
General Veterinary
Reference35 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68(6): 394-424. 2. Gao, Y., Dorn, P., Liu, S., Deng, H., Hall, S.R.R., Peng, R.W., Schmid, R.A. and Marti, T.M. (2019) Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. Cancer Cell Int. 19(1): 317. 3. Onuki, T., Morita, E., Sakamoto, N., Nagai, Y., Sata, M. and Hagiwara, K. (2018) Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol. Case Rep., 6(6): e00334. 4. Park, J., Jeong, D., Song, M. and Kim, B. (2021) Recent advances in anti-metastatic approaches of herbal medicines in 5 major cancers: From traditional medicine to modern drug discovery. Antioxidants 10(4): 527. 5. Yoon, S., Han, J.J., Baek, S.K., Kim, H.J. and Maeng, C.H. (2020) Prembolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of lung: A case study. Lung Cancer, 147: 21-25.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|